{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:13:18Z","timestamp":1792451598002,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372643"],"award-info":[{"award-number":["82372643"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503175"],"award-info":[{"award-number":["82503175"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai","doi-asserted-by":"publisher","award":["25ZR1402438"],"award-info":[{"award-number":["25ZR1402438"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai","doi-asserted-by":"publisher","award":["25ZR1401303"],"award-info":[{"award-number":["25ZR1401303"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"DOI":"10.1038\/s41423-026-01419-6","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:45:35Z","timestamp":1778082335000},"page":"701-718","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["USP21 drives immune evasion in colorectal cancer via deubiquitination and stabilization of \u03b2-catenin"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8374-211X","authenticated-orcid":false,"given":"Mantang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3709-291X","authenticated-orcid":false,"given":"Bingjie","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3396-5269","authenticated-orcid":false,"given":"Menghua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushuai","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongwang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senlin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"1419_CR1","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","volume":"394","author":"E Dekker","year":"2019","unstructured":"Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394:1467\u201380.","journal-title":"Lancet."},{"key":"1419_CR2","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207\u201318.","journal-title":"N Engl J Med"},{"key":"1419_CR3","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1200\/JCO.21.01874","volume":"40","author":"DM O\u2019Malley","year":"2022","unstructured":"O\u2019Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, De Jesus Acosta A, et al. Pembrolizumabin patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 Study. J Clin Oncol. 2022;40:752\u201361.","journal-title":"J Clin Oncol"},{"key":"1419_CR4","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1056\/NEJMc2036233","volume":"384","author":"L Battistuzzi","year":"2021","unstructured":"Battistuzzi L, Puccini A, Sciallero S. Microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2021;384:971\u201372.","journal-title":"N Engl J Med"},{"key":"1419_CR5","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1200\/JCO.22.01351","volume":"41","author":"K Ludford","year":"2023","unstructured":"Ludford K, Ho WJ, Thomas JV, Raghav KPS, Murphy MB, Fleming ND, et al. Neoadjuvant Pembrolizumabin localized microsatellite instability high\/deficient mismatch repair solid tumors. J Clin Oncol. 2023;41:2181\u201390.","journal-title":"J Clin Oncol"},{"key":"1419_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41575-021-00569-4","volume":"19","author":"K Ganesh","year":"2022","unstructured":"Ganesh K. Optimizing immunotherapy for colorectal cancer. Nat Rev Gastroenterol Hepatol. 2022;19:93\u201394.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1419_CR7","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, et al. Durable clinical benefit withNivolumab Plus Ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastaticcolorectal cancer. J Clin Oncol. 2018;36:773\u20139.","journal-title":"J Clin Oncol"},{"key":"1419_CR8","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","volume":"16","author":"K Ganesh","year":"2019","unstructured":"Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, et al. Immunotherapy in colorectalcancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16:361\u201375.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1419_CR9","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","volume":"21","author":"S Jhunjhunwala","year":"2021","unstructured":"Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumorimmunogenicity and immune evasion. Nat Rev Cancer. 2021;21:298\u2013312.","journal-title":"Nat Rev Cancer"},{"key":"1419_CR10","doi-asserted-by":"crossref","unstructured":"Wei W, Li H, Tian S, Zhang C, Liu J, Tao W, et al. Asparagine drives immune evasion in bladder cancervia RIG-I stability and type I IFN signaling. J Clin Invest, 2025,135.","DOI":"10.1172\/JCI186648"},{"key":"1419_CR11","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41568-023-00615-0","volume":"23","author":"T Gebhardt","year":"2023","unstructured":"Gebhardt T, Park SL, Parish IA. Stem-like exhausted and memory CD8(+) T cells in cancer. Nat RevCancer. 2023;23:780\u2013798.","journal-title":"Nat RevCancer"},{"key":"1419_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.cell.2022.12.028","volume":"186","author":"JR Lin","year":"2023","unstructured":"Lin JR, Wang S, Coy S, Chen YA, Yapp C, Tyler M, et al. Multiplexed 3D atlas of state transitions andimmune interaction in colorectal cancer. Cell. 2023;186:363\u201381.e319.","journal-title":"Cell"},{"key":"1419_CR13","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/s41586-024-07135-3","volume":"627","author":"N Goto","year":"2024","unstructured":"Goto N, Westcott PMK, Goto S, Imada S, Taylor MS, Eng G, et al. SOX17 enables immune evasion of early colorectal adenomas and cancers. Nature. 2024;627:636\u201345.","journal-title":"Nature."},{"key":"1419_CR14","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1126\/science.abb9847","volume":"370","author":"S Krishna","year":"2020","unstructured":"Krishna S, Lowery FJ, Copeland AR, Bahadiroglu E, Mukherjee R, Jia L, et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science. 2020;370:1328\u201334.","journal-title":"Science"},{"key":"1419_CR15","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R, et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med. 2019;25:1251\u201359.","journal-title":"Nat Med"},{"key":"1419_CR16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s13046-023-02805-y","volume":"42","author":"H Gao","year":"2023","unstructured":"Gao H, Yin J, Ji C, Yu X, Xue J, Guan X, et al. Targeting ubiquitin specific proteases (USPs) in cancerimmunotherapy: from basic research to preclinical application. J Exp Clin Cancer Res. 2023;42:225.","journal-title":"J Exp Clin Cancer Res"},{"key":"1419_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrd.2017.152","volume":"17","author":"JA Harrigan","year":"2018","unstructured":"Harrigan JA, Jacq X, Martin NM, Jackson SP. Deubiquitylating enzymes and drug discovery: emergingopportunities. Nat Rev Drug Discov. 2018;17:57\u201378.","journal-title":"Nat Rev Drug Discov"},{"key":"1419_CR18","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41568-023-00633-y","volume":"23","author":"G Dewson","year":"2023","unstructured":"Dewson G, Eichhorn PJA, Komander D. Deubiquitinases in cancer. Nat Rev Cancer. 2023;23:842\u2013862.","journal-title":"Nat Rev Cancer"},{"key":"1419_CR19","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.3389\/fonc.2020.01289","volume":"10","author":"X Huang","year":"2020","unstructured":"Huang X, Zhang X, Xu J, Wang X, Zhang G, Tang T, et al. Deubiquitinating enzyme: a potential secondary checkpoint of cancer immunity. Front Oncol. 2020;10:1289.","journal-title":"Front Oncol"},{"key":"1419_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56564-9","volume":"16","author":"N Shao","year":"2025","unstructured":"Shao N, Xi L, Lv Y, Idris M, Zhang L, Cao Y, et al. USP5 stabilizes YTHDF1 to control cancer immune surveillance through mTORC1-mediated phosphorylation. Nat Commun. 2025;16:1313.","journal-title":"Nat Commun"},{"key":"1419_CR21","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.7150\/ijbs.90774","volume":"20","author":"X Xu","year":"2024","unstructured":"Xu X, Chen Y, Shao S, Wang J, Shan J, Wang Y, et al. USP21 deubiquitinates and stabilizes HSP90 and ENO1 to promote aerobic glycolysis and proliferation in cholangiocarcinoma. Int J Biol Sci. 2024;20:1492\u2013508.","journal-title":"Int J Biol Sci"},{"key":"1419_CR22","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1101\/gad.326314.119","volume":"33","author":"P Hou","year":"2019","unstructured":"Hou P, Ma X, Zhang Q, Wu CJ, Liao W, Li J, et al. USP21 deubiquitinase promotes pancreas cancer cell stemness via Wnt pathway activation. Genes Dev. 2019;33:1361\u201366.","journal-title":"Genes Dev"},{"key":"1419_CR23","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1016\/j.celrep.2019.02.054","volume":"26","author":"A Arceci","year":"2019","unstructured":"Arceci A, Bonacci T, Wang X, Stewart K, Damrauer JS, Hoadley KA, et al. FOXM1 deubiquitination by USP21 regulates cell cycle progression and Paclitaxel sensitivity in basal-like breast cancer. Cell Rep. 2019;26:3076\u201386.e3076.","journal-title":"Cell Rep"},{"key":"1419_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0523-z","volume":"9","author":"W Li","year":"2018","unstructured":"Li W, Cui K, Prochownik EV, Li Y. The deubiquitinase USP21 stabilizes MEK2 to promote tumor growth. Cell Death Dis. 2018;9:482.","journal-title":"Cell Death Dis"},{"key":"1419_CR25","doi-asserted-by":"publisher","first-page":"eabo4116","DOI":"10.1126\/sciadv.abo4116","volume":"8","author":"E Montauti","year":"2022","unstructured":"Montauti E, Weinberg SE, Chu P, Chaudhuri S, Mani NL, Iyer R, et al. A deubiquitination module essential for T(reg) fitness in the tumor microenvironment. Sci Adv. 2022;8:eabo4116.","journal-title":"Sci Adv"},{"key":"1419_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13559","volume":"7","author":"Y Li","year":"2016","unstructured":"Li Y, Lu Y, Wang S, Han Z, Zhu F, Ni Y, et al. USP21 prevents the generation of T-helper-1-like Treg cells. Nat Commun. 2016;7:13559.","journal-title":"Nat Commun"},{"key":"1419_CR27","doi-asserted-by":"publisher","first-page":"eadg7740","DOI":"10.1126\/scitranslmed.adg7740","volume":"16","author":"JH Ding","year":"2024","unstructured":"Ding JH, Xiao Y, Yang F, Song XQ, Xu Y, Ding XH, et al. Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer. Sci Transl Med. 2024;16:eadg7740.","journal-title":"Sci Transl Med"},{"key":"1419_CR28","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1084\/jem.20122844","volume":"211","author":"Y Fan","year":"2014","unstructured":"Fan Y, Mao R, Yu Y, Liu S, Shi Z, Cheng J, et al. USP21 negatively regulates antiviral response by acting as a RIG-I deubiquitinase. J Exp Med. 2014;211:313\u201328.","journal-title":"J Exp Med"},{"key":"1419_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56714-z","volume":"16","author":"W Jiang","year":"2025","unstructured":"Jiang W, Guan B, Sun H, Mi Y, Cai S, Wan R, et al. WNT11 Promotes immune evasion and resistance to Anti-PD-1 therapy in liver metastasis. Nat Commun. 2025;16:1429.","journal-title":"Nat Commun"},{"key":"1419_CR30","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","volume":"25","author":"JJ Luke","year":"2019","unstructured":"Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF. WNT\/\u03b2-catenin pathway activation correlates with immune exclusion across human cancers. Clin Cancer Res. 2019;25:3074\u201383.","journal-title":"Clin Cancer Res"},{"key":"1419_CR31","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1158\/0008-5472.CAN-19-3074","volume":"80","author":"L Ji","year":"2020","unstructured":"Ji L, Qian W, Gui L, Ji Z, Yin P, Lin GN, et al. Blockade of \u03b2-Catenin-induced CCL28 suppresses gastric cancer progression via inhibition of Treg cell infiltration. Cancer Res. 2020;80:2004\u201316.","journal-title":"Cancer Res"},{"key":"1419_CR32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41568-020-00307-z","volume":"21","author":"JM Bugter","year":"2021","unstructured":"Bugter JM, Fenderico N, Maurice MM. Mutations and mechanisms of WNT pathway tumor suppressorsin cancer. Nat Rev Cancer. 2021;21:5\u201321.","journal-title":"Nat Rev Cancer"},{"key":"1419_CR33","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509\u201320.","journal-title":"N Engl J Med"},{"key":"1419_CR34","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco SA, Calderon-Copete S, Pais Ferreira D, et al. Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity. 2019;50:195\u2013211.e110.","journal-title":"Immunity."},{"key":"1419_CR35","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1021\/acs.jmedchem.2c01933","volume":"66","author":"F G\u00f6ricke","year":"2023","unstructured":"G\u00f6ricke F, Vu V, Smith L, Scheib U, B\u00f6hm R, Akkilic N, et al. Discovery and characterization of BAY-805, a potent and selective inhibitor of ubiquitin-specific Protease USP21. J Med Chem. 2023;66:3431\u201347.","journal-title":"J Med Chem"},{"key":"1419_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-3-030-36667-4_3","volume":"1231","author":"N Mukaida","year":"2020","unstructured":"Mukaida N, Sasaki SI, Baba T. CCL4 signaling in the tumor microenvironment. Adv Exp Med Biol. 2020;1231:23\u201332.","journal-title":"Adv Exp Med Biol"},{"key":"1419_CR37","doi-asserted-by":"publisher","first-page":"e2202528","DOI":"10.1002\/advs.202202528","volume":"9","author":"CC Zheng","year":"2022","unstructured":"Zheng CC, Liao L, Liu YP, Yang YM, He Y, Zhang GG, et al. Blockade of nuclear \u03b2-Catenin signaling viadirect targeting of RanBP3 with NU2058 induces cell senescence to suppress colorectal Tumorigenesis. Adv Sci. 2022;9:e2202528.","journal-title":"Adv Sci"},{"key":"1419_CR38","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic \u03b2-catenin signaling prevents antitumor immunity. Nature. 2015;523:231\u20135.","journal-title":"Nature"},{"key":"1419_CR39","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41571-024-00943-6","volume":"21","author":"CJM Williams","year":"2024","unstructured":"Williams CJM, Peddle AM, Kasi PM, Seligmann JF, Roxburgh CS, Middleton GW, et al. Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response. Nat Rev Clin Oncol. 2024;21:839\u201351.","journal-title":"Nat Rev Clin Oncol"},{"key":"1419_CR40","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S2468-1253(24)00091-8","volume":"9","author":"D Wankhede","year":"2024","unstructured":"Wankhede D, Yuan T, Kloor M, Halama N, Brenner H, Hoffmeister M. Clinical significance of combinedtumor-infiltrating lymphocytes and microsatellite instability status in colorectal cancer: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2024;9:609\u201319.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1419_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41392-020-0107-0","volume":"5","author":"L Deng","year":"2020","unstructured":"Deng L, Meng T, Chen L, Wei W, Wang P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther. 2020;5:11.","journal-title":"Signal Transduct Target Ther"},{"key":"1419_CR42","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.immuni.2013.05.018","volume":"39","author":"J van Loosdregt","year":"2013","unstructured":"van Loosdregt J, Fleskens V, Fu J, Brenkman AB, Bekker CP, Pals CE, et al. Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. Immunity. 2013;39:259\u201371.","journal-title":"Immunity"},{"key":"1419_CR43","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/2326-6066.CIR-19-0661","volume":"8","author":"J Li","year":"2020","unstructured":"Li J, Yuan S, Norgard RJ, Yan F, Yamazoe T, Blanco A, et al. Tumor cell-intrinsic USP22 suppresses antitumor immunity in pancreatic cancer. Cancer Immunol Res. 2020;8:282\u201391.","journal-title":"Cancer Immunol Res"},{"key":"1419_CR44","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41418-022-01102-z","volume":"30","author":"H Yang","year":"2023","unstructured":"Yang H, Zhang X, Lao M, Sun K, He L, Xu J, et al. Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer. Cell Death Differ. 2023;30:560\u201375.","journal-title":"Cell Death Differ"},{"key":"1419_CR45","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1158\/0008-5472.CAN-09-1942","volume":"70","author":"H Potu","year":"2010","unstructured":"Potu H, Sgorbissa A, Brancolini C. Identification of USP18 as an important regulator of thesusceptibility to IFN-alpha and drug-induced apoptosis. Cancer Res. 2010;70:655\u2013665.","journal-title":"Cancer Res"},{"key":"1419_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29401-6","volume":"13","author":"W Xiong","year":"2022","unstructured":"Xiong W, Gao X, Zhang T, Jiang B, Hu MM, Bu X, et al. USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy. Nat Commun. 2022;13:1700.","journal-title":"Nat Commun"},{"key":"1419_CR47","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41568-023-00560-y","volume":"23","author":"G Oliveira","year":"2023","unstructured":"Oliveira G, Wu CJ. Dynamics and specificities of T cells in cancer immunotherapy. Nat Rev Cancer. 2023;23:295\u2013316.","journal-title":"Nat Rev Cancer"},{"key":"1419_CR48","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1158\/0008-5472.CAN-22-2838","volume":"83","author":"HR Park","year":"2023","unstructured":"Park HR, Shiva A, Cummings P, Kim S, Kim S, Lee E, et al. Angiopoietin-2-dependent spatial vascular destabilization promotes T-cell exclusion and limits immunotherapy in melanoma. Cancer Res. 2023;83:1968\u201383.","journal-title":"Cancer Res"},{"key":"1419_CR49","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/s41556-024-01462-3","volume":"26","author":"RY Shi","year":"2024","unstructured":"Shi RY, Zhou N, Xuan L, Jiang ZH, Xia J, Zhu JM, et al. Trafficking circuit of CD8(+) T cells between the intestine and bone marrow governs antitumour immunity. Nat Cell Biol. 2024;26:1346\u201358.","journal-title":"Nat Cell Biol"},{"key":"1419_CR50","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1016\/j.ccell.2024.10.008","volume":"42","author":"C Yang","year":"2024","unstructured":"Yang C, Geng H, Yang X, Ji S, Liu Z, Feng H, et al. Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy. Cancer Cell. 2024;42:2064\u201381.e2019.","journal-title":"Cancer Cell"},{"key":"1419_CR51","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/s41423-022-00848-3","volume":"19","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Chen M, Xu D, Li TE, Zhang Z, Li JH, et al. The combination of PD-1 blockade with interferon-\u03b1 has a synergistic effect on hepatocellular carcinoma. Cell Mol Immunol. 2022;19:726\u201337.","journal-title":"Cell Mol Immunol"},{"key":"1419_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43548-w","volume":"14","author":"S Shang","year":"2023","unstructured":"Shang S, Yang C, Chen F, Xiang RS, Zhang H, Dai SY, et al. ID1 expressing macrophages support cancer cell stemness and limit CD8(+) T-cell infiltration in colorectal cancer. Nat Commun. 2023;14:7661.","journal-title":"Nat Commun"},{"key":"1419_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02354-2","volume":"24","author":"J Yang","year":"2025","unstructured":"Yang J, Lu X, Cai Q, Liu M, Xia T, Hong D, et al. Loss of TACC2 impairs chemokine CCL3 and CCL4 expression and reduces response to anti-PD-1 therapy in soft tissue sarcoma. Mol Cancer. 2025;24:158.","journal-title":"Mol Cancer"},{"key":"1419_CR54","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00262-024-03909-w","volume":"74","author":"Y Tian","year":"2025","unstructured":"Tian Y, Zhang L, Ping Y, Zhang Z, Yao C, Shen C, et al. CCR5 and IL-12 coexpression in CAR T cell simproves antitumor efficacy by reprogramming tumor microenvironment in solid tumors. CancerImmunol Immunother. 2025;74:55.","journal-title":"CancerImmunol Immunother"},{"key":"1419_CR55","doi-asserted-by":"crossref","unstructured":"Rawat K, Tewari A, Li X, Mara AB, King WT, Gibbings SL, et al. CCL5-producing migratory dendritic cells guide CCR5+ monocytes into the draining lymph nodes. J Exp Med. 2023:220.","DOI":"10.1084\/jem.20222129"},{"key":"1419_CR56","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/76957","volume":"1","author":"J Aliberti","year":"2000","unstructured":"Aliberti J, Reis e Sousa C, Schito M, Hieny S, Wells T, Huffnagle GB, et al. CCR5 provides a signal formicrobial induced production of IL-12 by CD8 alpha+ dendritic cells. Nat Immunol. 2000;1:83\u201387.","journal-title":"Nat Immunol"},{"key":"1419_CR57","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1146\/annurev-med-052010-145454","volume":"63","author":"TJ Wilkin","year":"2012","unstructured":"Wilkin TJ, Gulick RM. CCR5 antagonism in HIV infection: current concepts and future opportunities. Annu Rev Med. 2012;63:81\u201393.","journal-title":"Annu Rev Med"},{"key":"1419_CR58","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","volume":"7","author":"J Liu","year":"2022","unstructured":"Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, et al. Wnt\/\u03b2-catenin signaling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7:3.","journal-title":"Signal Transduct Target Ther"},{"key":"1419_CR59","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41392-025-02142-w","volume":"10","author":"C Xue","year":"2025","unstructured":"Xue C, Chu Q, Shi Q, Zeng Y, Lu J, Li L. Wnt signaling pathways in biology and disease: mechanismsand therapeutic advances. Signal Transduct Target Ther. 2025;10:106.","journal-title":"Signal Transduct Target Ther"},{"key":"1419_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28286-9","volume":"13","author":"C Miete","year":"2022","unstructured":"Miete C, Solis GP, Koval A, Br\u00fcckner M, Katanaev VL, Behrens J, et al. G\u03b1i2-induced conductin\/axin2 condensates inhibit Wnt\/\u03b2-catenin signaling and suppress cancer growth. Nat Commun. 2022;13:674.","journal-title":"Nat Commun"},{"key":"1419_CR61","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-024-01563-4","volume":"17","author":"P Song","year":"2024","unstructured":"Song P, Gao Z, Bao Y, Chen L, Huang Y, Liu Y, et al. Wnt\/\u03b2-catenin signaling pathway in carcinogenesisand cancer therapy. J Hematol Oncol. 2024;17:46.","journal-title":"J Hematol Oncol"}],"container-title":["Cellular &amp; Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41423-026-01419-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-026-01419-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-026-01419-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T22:02:29Z","timestamp":1780178549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41423-026-01419-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":61,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["1419"],"URL":"https:\/\/doi.org\/10.1038\/s41423-026-01419-6","relation":{},"ISSN":["2042-0226"],"issn-type":[{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}